Literature DB >> 14729088

Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.

Ana Vila1, Alejandro Sánchez, Kevin Janes, Isabel Behrens, Thomas Kissel, José Luis Vila Jato, María José Alonso.   

Abstract

High molecular weight (Mw) chitosan (CS) solutions have already been proposed as vehicles for nasal immunization. The aim of the present work was to investigate the potential utility of low Mw CS in the form of nanoparticles as new long-term nasal vaccine delivery vehicles. For this purpose, CS of low Mws (23 and 38 kDa) was obtained previously by a depolymerization process of the commercially available CS (70 kDa). Tetanus toxoid (TT), used as a model antigen, was entrapped within CS nanoparticles by an ionic cross-linking technique. TT-loaded nanoparticles were first characterized for their size, electrical charge, loading efficiency and in vitro release of antigenically active toxoid. The nanoparticles were then administered intranasally to conscious mice in order to study their feasibility as vaccine carriers. CS nanoparticles were also labeled with FITC-BSA and their interaction with the rat nasal mucosa examined by confocal laser scanning microcopy (CLSM). Irrespective of the CS Mw, the nanoparticles were in the 350 nm size range, and exhibited a positive electrical charge (+40 mV) and associated TT quite efficiently (loading efficiency: 50-60%). In vitro release studies showed an initial burst followed by an extended release of antigenically active toxoid. Following intranasal administration, TT-loaded nanoparticles elicited an increasing and long-lasting humoral immune response (IgG concentrations) as compared to the fluid vaccine. Similarly, the mucosal response (IgA levels) at 6 months post-administration of TT-loaded CS nanoparticles was significantly higher than that obtained for the fluid vaccine. The CLSM images indicated that CS nanoparticles can cross the nasal epithelia and, hence, transport the associated antigen. Interestingly, the ability of these nanoparticles to provide improved access to the associated antigen to the immune system was not significantly affected by the CS Mw. Indeed, high and long-lasting responses could be obtained using low Mw CS molecules. Furthermore, the response was not influenced by the CS dose (70-200 microg), achieving a significant response for a very low CS dose. In conclusion, nanoparticles made of low Mw CS are promising carriers for nasal vaccine delivery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729088     DOI: 10.1016/j.ejpb.2003.09.006

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  62 in total

1.  Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin.

Authors:  Stephen Soukasene; Daniel J Toft; Tyson J Moyer; Hsuming Lu; Hyung-Kun Lee; Stephany M Standley; Vincent L Cryns; Samuel I Stupp
Journal:  ACS Nano       Date:  2011-11-01       Impact factor: 15.881

2.  Chitosan-based nanoparticles as a sustained protein release carrier for tissue engineering applications.

Authors:  Yaping Hou; Junli Hu; Hyejin Park; Min Lee
Journal:  J Biomed Mater Res A       Date:  2012-01-24       Impact factor: 4.396

3.  Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery.

Authors:  C Prego; M Fabre; D Torres; M J Alonso
Journal:  Pharm Res       Date:  2006-03-16       Impact factor: 4.200

Review 4.  Biopolymeric nanoparticles.

Authors:  Sushmitha Sundar; Joydip Kundu; Subhas C Kundu
Journal:  Sci Technol Adv Mater       Date:  2010-02-26       Impact factor: 8.090

5.  Antimicrobial Activity of Chitosan Film Forming Solution Enriched with Essential Oils; an in Vitro Assay.

Authors:  Kana Jean Raphaël; Amir Meimandipour
Journal:  Iran J Biotechnol       Date:  2017-08-19       Impact factor: 1.671

Review 6.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

7.  Chitosan-zinc-insulin complex incorporated thermosensitive polymer for controlled delivery of basal insulin in vivo.

Authors:  Mayura Oak; Jagdish Singh
Journal:  J Control Release       Date:  2012-08-07       Impact factor: 9.776

8.  Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice.

Authors:  Mohammad Ali Danesh-Bahreini; Javad Shokri; Afshin Samiei; Eskandar Kamali-Sarvestani; Mohammad Barzegar-Jalali; Soliman Mohammadi-Samani
Journal:  Int J Nanomedicine       Date:  2011-04-20

9.  Evaluation of mucoadhesive PLGA microparticles for nasal immunization.

Authors:  Dilip Pawar; Amit K Goyal; Sharad Mangal; Neeraj Mishra; Bhuvaneshwar Vaidya; Shailja Tiwari; Arvind K Jain; Suresh P Vyas
Journal:  AAPS J       Date:  2010-01-15       Impact factor: 4.009

10.  Therapeutic effects of Holmium-166 chitosan complex in rat brain tumor model.

Authors:  Ryoong Huh; Yong Sook Park; Jong Doo Lee; Young Sun Chung; Yong Gou Park; Sang Sup Chung; Jin Woo Chang
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.